KR102201086B9 - Il-2 단백질 및 cd80 단백질을 포함하는 융합단백질 및 이의 용도 - Google Patents

Il-2 단백질 및 cd80 단백질을 포함하는 융합단백질 및 이의 용도

Info

Publication number
KR102201086B9
KR102201086B9 KR1020190113659A KR20190113659A KR102201086B9 KR 102201086 B9 KR102201086 B9 KR 102201086B9 KR 1020190113659 A KR1020190113659 A KR 1020190113659A KR 20190113659 A KR20190113659 A KR 20190113659A KR 102201086 B9 KR102201086 B9 KR 102201086B9
Authority
KR
South Korea
Prior art keywords
protein
fusion
fusion protein
Prior art date
Application number
KR1020190113659A
Other languages
English (en)
Other versions
KR20200032009A (ko
KR102201086B1 (ko
Inventor
장명호
Original Assignee
(주)지아이이노베이션
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by (주)지아이이노베이션 filed Critical (주)지아이이노베이션
Publication of KR20200032009A publication Critical patent/KR20200032009A/ko
Priority to KR1020210000775A priority Critical patent/KR102558191B1/ko
Application granted granted Critical
Publication of KR102201086B1 publication Critical patent/KR102201086B1/ko
Publication of KR102201086B9 publication Critical patent/KR102201086B9/ko

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/55—IL-2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70532—B7 molecules, e.g. CD80, CD86
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62—DNA sequences coding for fusion proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/31—Fusion polypeptide fusions, other than Fc, for prolonged plasma life, e.g. albumin

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Cell Biology (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Epidemiology (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
KR1020190113659A 2018-09-17 2019-09-16 Il-2 단백질 및 cd80 단백질을 포함하는 융합단백질 및 이의 용도 KR102201086B1 (ko)

Priority Applications (1)

Application Number Priority Date Filing Date Title
KR1020210000775A KR102558191B1 (ko) 2018-09-17 2021-01-05 Il-2 단백질 및 cd80 단백질을 포함하는 융합단백질 및 이의 용도

Applications Claiming Priority (8)

Application Number Priority Date Filing Date Title
KR20180110698 2018-09-17
KR1020180110698 2018-09-17
KR20190001867 2019-01-07
KR1020190001867 2019-01-07
US201962832013P 2019-04-10 2019-04-10
US62/832,013 2019-04-10
KR1020190053436 2019-05-08
KR20190053436 2019-05-08

Related Child Applications (1)

Application Number Title Priority Date Filing Date
KR1020210000775A Division KR102558191B1 (ko) 2018-09-17 2021-01-05 Il-2 단백질 및 cd80 단백질을 포함하는 융합단백질 및 이의 용도

Publications (3)

Publication Number Publication Date
KR20200032009A KR20200032009A (ko) 2020-03-25
KR102201086B1 KR102201086B1 (ko) 2021-01-11
KR102201086B9 true KR102201086B9 (ko) 2022-10-21

Family

ID=69887592

Family Applications (2)

Application Number Title Priority Date Filing Date
KR1020190113659A KR102201086B1 (ko) 2018-09-17 2019-09-16 Il-2 단백질 및 cd80 단백질을 포함하는 융합단백질 및 이의 용도
KR1020210000775A KR102558191B1 (ko) 2018-09-17 2021-01-05 Il-2 단백질 및 cd80 단백질을 포함하는 융합단백질 및 이의 용도

Family Applications After (1)

Application Number Title Priority Date Filing Date
KR1020210000775A KR102558191B1 (ko) 2018-09-17 2021-01-05 Il-2 단백질 및 cd80 단백질을 포함하는 융합단백질 및 이의 용도

Country Status (15)

Country Link
US (3) US11492384B2 (ko)
JP (2) JP7085644B2 (ko)
KR (2) KR102201086B1 (ko)
CN (1) CN111971295A (ko)
BR (1) BR112020015030A2 (ko)
CA (1) CA3086486A1 (ko)
CL (1) CL2020001872A1 (ko)
IL (1) IL275592B (ko)
MX (1) MX2020007072A (ko)
PE (1) PE20201418A1 (ko)
PH (1) PH12020551026A1 (ko)
SG (1) SG11202005873QA (ko)
TW (2) TWI824258B (ko)
WO (1) WO2020060122A1 (ko)
ZA (1) ZA202003645B (ko)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2756236C2 (ru) * 2016-06-20 2021-09-28 Кимаб Лимитед PD-L1 специфические антитела
EP4063491A4 (en) * 2019-11-20 2023-02-01 GI Cell, Inc. COMPOSITION FOR GROWING NATURAL KILLER CELLS AND METHOD OF MAKING NATURAL KILLER CELLS USING THE SAME
WO2021187904A1 (ko) * 2020-03-18 2021-09-23 (주)지아이이노베이션 Il-2 단백질 및 cd80 단백질 단편 또는 이의 변이체를 포함하는 융합단백질 및 이의 용도
CN115666522A (zh) 2020-03-18 2023-01-31 Gi医诺微新 包含il-2蛋白和cd80蛋白的融合蛋白制剂
CA3175457A1 (en) * 2020-03-18 2021-09-23 Gi Innovation, Inc. Pharmaceutical composition for treating cancer, comprising fusion protein comprising il-2 protein and cd80 protein and anticancer drug
EP4130027A1 (en) * 2020-03-31 2023-02-08 Hanmi Pharm. Co., Ltd. Novel immunoactive interleukin 2 analog
CN115943165A (zh) * 2020-05-25 2023-04-07 北京比洋生物技术有限公司 Fc-CD80融合蛋白和其缀合物以及它们的用途
KR102373965B1 (ko) * 2020-06-05 2022-03-15 (주)지아이이노베이션 Ｉｌ-２ 단백질 및 ｃｄ８０ 단백질을 포함하는 융합단백질을 포함하는 방사선 치료 증진용 약학적 조성물
KR102313505B1 (ko) * 2020-06-30 2021-10-18 (주)지아이이노베이션 항-lag-3 항체 및 il-2를 포함하는 융합단백질 및 이의 용도
US20230322881A1 (en) * 2020-08-31 2023-10-12 Gi Cell, Inc. Fusion protein including il15 protein, il15 receptor alpha protein, fc domain, and il2 protein, and use thereof
TW202406932A (zh) 2020-10-22 2024-02-16 美商基利科學股份有限公司 介白素2-Fc融合蛋白及使用方法
WO2022057696A2 (zh) * 2021-09-08 2022-03-24 中南大学湘雅医院 一种重组蛋白的编码序列、重组蛋白及其单克隆抗体的制备方法
WO2023234743A1 (ko) * 2022-06-03 2023-12-07 (주)지아이이노베이션 항-tigit 항체를 포함하는 이중 특이적 항체 및 이의 용도
WO2023249425A1 (ko) * 2022-06-22 2023-12-28 ㈜지아이이노베이션 항-cd73 항체 및 il-2를 포함하는 융합단백질 및 이의 용도
WO2024063546A1 (ko) * 2022-09-20 2024-03-28 주식회사 지아이바이옴 락토바실러스 플란타룸 균주의 병용 요법 및 이를 이용한 암 치료 방법

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ZA842025B (en) * 1983-03-21 1984-11-28 Hoffmann La Roche Interleuken-2
CN86104525A (zh) * 1985-07-31 1987-02-25 武田药品工业株式会社 人类白细胞介素-2的分析方法和试剂
US5229109A (en) 1992-04-14 1993-07-20 Board Of Regents, The University Of Texas System Low toxicity interleukin-2 analogues for use in immunotherapy
DZ2788A1 (fr) * 1998-05-15 2003-12-01 Bayer Ag Agonistes et antagonistes selectifs à IL-2.
GB9810999D0 (en) 1998-05-21 1998-07-22 Goken Joop Materials and methods relating to the expression of genes
US7829084B2 (en) 2001-01-17 2010-11-09 Trubion Pharmaceuticals, Inc. Binding constructs and methods for use thereof
WO2003015697A2 (en) 2001-08-13 2003-02-27 University Of Southern California Interleukin-2 mutants with reduced toxicity
BR0214650A (pt) 2001-12-04 2005-05-03 Merck Patent Gmbh Imunocitoquinas com seletividade modulada
WO2005091956A2 (en) * 2004-03-05 2005-10-06 Chiron Corporation In vitro test system for predicting patient tolerability of therapeutic agents
FI2402754T4 (fi) * 2006-03-06 2023-10-06 Ei-kiinteärakenteisia rekombinantteja polymeerejä ja niiden käyttötapoja
CA2656700A1 (en) 2006-07-06 2008-01-10 Merck Patent Gesellschaft Mit Beschraenkter Haftung Compositions and methods for enhancing the efficacy of il-2 mediated immune responses
KR20100058541A (ko) * 2007-08-15 2010-06-03 아뮤닉스 인코포레이티드 생물학적 활성 폴리펩티드의 특성을 변경하기 위한 조성물 및 방법
CU23923B1 (es) 2010-11-12 2013-07-31 Ct De Inmunología Molecular Polipéptidos derivados de la il-2 con actividad agonista
CN105440123B (zh) 2011-02-10 2020-10-09 罗切格利卡特公司 突变体白介素-2多肽
EA201892619A1 (ru) 2011-04-29 2019-04-30 Роше Гликарт Аг Иммуноконъюгаты, содержащие мутантные полипептиды интерлейкина-2
US8956619B2 (en) 2011-10-25 2015-02-17 University Of Maryland, Baltimore County Soluble CD80 as a therapeutic to reverse immune supression in cancer patients
ES2699599T3 (es) 2013-03-15 2019-02-11 Abbvie Biotherapeutics Inc Variantes de Fc
PL3186283T3 (pl) * 2014-08-29 2020-05-18 F. Hoffmann-La Roche Ag Terapia skojarzona z zastosowaniem skierowanej przeciw nowotworowi, opartej na wariancie IL2 immunocytokiny oraz przeciwciał przeciwko ludzkiemu ligandowi programowanej śmierci PD-L1
US10273281B2 (en) * 2015-11-02 2019-04-30 Five Prime Therapeutics, Inc. CD80 extracellular domain polypeptides and their use in cancer treatment
RU2756236C2 (ru) * 2016-06-20 2021-09-28 Кимаб Лимитед PD-L1 специфические антитела
US9567399B1 (en) 2016-06-20 2017-02-14 Kymab Limited Antibodies and immunocytokines
ES2928718T3 (es) 2017-04-03 2022-11-22 Hoffmann La Roche Inmunoconjugados de un anticuerpo anti-PD-1 con una IL-2 mutante o con IL-15

Also Published As

Publication number Publication date
PH12020551026A1 (en) 2021-09-06
EP3715367A1 (en) 2020-09-30
TW202136288A (zh) 2021-10-01
IL275592B (en) 2022-02-01
WO2020060122A1 (ko) 2020-03-26
KR20210008110A (ko) 2021-01-20
ZA202003645B (en) 2022-09-28
CN111971295A (zh) 2020-11-20
US20220389070A1 (en) 2022-12-08
TW202028227A (zh) 2020-08-01
SG11202005873QA (en) 2020-07-29
TWI824258B (zh) 2023-12-01
CL2020001872A1 (es) 2020-12-18
BR112020015030A2 (pt) 2021-03-16
TWI755630B (zh) 2022-02-21
KR20200032009A (ko) 2020-03-25
CA3086486A1 (en) 2020-03-26
US11492384B2 (en) 2022-11-08
JP7085644B2 (ja) 2022-06-16
KR102201086B1 (ko) 2021-01-11
PE20201418A1 (es) 2020-12-09
AU2019343850A1 (en) 2020-06-25
US20220380781A1 (en) 2022-12-01
IL275592A (en) 2020-08-31
JP2021511081A (ja) 2021-05-06
MX2020007072A (es) 2020-11-11
US20200369740A1 (en) 2020-11-26
JP2022115876A (ja) 2022-08-09
KR102558191B1 (ko) 2023-07-24
EP3715367A4 (en) 2021-05-05

Similar Documents

Publication Publication Date Title
KR102201086B9 (ko) Il-2 단백질 및 cd80 단백질을 포함하는 융합단백질 및 이의 용도
EP3806889A4 (en) CYTOKINE-BASED FUSION PROTEINS AND THEIR USES
EP3623389A4 (en) FUSION PROTEIN WITH TGF RECEPTOR AND ITS MEDICAL USES
SG11202012004SA (en) Rna-targeting fusion protein compositions and methods for use
IL267861A (en) PD1-41BBL conjugate protein and methods of using it
IL280102A (en) Fusion protein containing PD1-4-1BBL and methods of using it
EP3565828B8 (en) A sirpalpha-4-1bbl fusion protein and methods of use thereof
EP3455263A4 (en) CD40L-FC FUSION POLYPEPTIDES AND METHODS OF USE THEREOF
EP3633034A4 (en) MODIFIED Cas9 PROTEIN, AND RELATED APPLICATION
EP3810172A4 (en) HETERODIMER PROTEINS AND THEIR USES
IL280103A (en) Fusion protein containing SIRPalpha-4-1BBL and methods of using it
EP3722305A4 (en) HM-3 FUSION PROTEIN AND USES THEREOF
ZA202000595B (en) Novel therapeutic enzyme fusion protein and use thereof
ZA202101250B (en) Novel crispr-associated protein and use thereof
SG11202110400QA (en) Fusion protein and use thereof
EP3668551A4 (en) APOM FC FUSION PROTEINS AND USES THEREOF
SG11202104912SA (en) Fusion protein and use thereof
IL287601A (en) Variant cd80 proteins and their uses
EP3831945A4 (en) PROTEIN HETERODIMER AND ITS USE
EP3816181A4 (en) IMPROVED FVIII FUSION PROTEIN AND ITS USE
EP3816186A4 (en) PD-L1 BINDING POLYPEPTIDE AND USE
EP3684796A4 (en) SUCCINATE REGULATORY POLYPEPTIDES AND USES
EP3425054C0 (en) CYTOCHROME MUTANT PROTEIN AND ITS USE
EP3611181A4 (en) ATP1A1T TARGETING POLYPEPTIDE AND USES
EP3875483A4 (en) FUSION PROTEIN WITH IDS AND ITS USE

Legal Events

Date Code Title Description
E902 Notification of reason for refusal
E701 Decision to grant or registration of patent right
GRNT Written decision to grant
G170 Re-publication after modification of scope of protection [patent]